top of page
Revolutionizing cancer treatment through next-generation immunotherapies
General
Medical
NEWS
05/21/2026
We entered into a research collaboration with Okayama University (Prof. Heiichiro Udono, Department of Metabolic Immune Regulation, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences). Research on the antitumor effects of liposomal formulations of existing small-molecule drugs.
04/01/2026
We entered into a research collaboration with Institute of Science Tokyo (Prof. Hideya Yuasa, School of Life Science and Technology). Research on antitumor compounds via drug repositioning will commence.
03/04/2025
We have received an assignment of a patent for the treatment of refractory cancer (pancreatic cancer, etc.) with three existing pharmaceuticals. The results of an investigator-initiated clinical trial in which two (Nivolumab + Metformin) of the three drugs described in the patent were administered have showed survival of more than 7 years in a patient among advanced pancreatic cancer （Sato R, Hotta K, Kubo T, et al. (February 14, 2025) Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Cureus 17(2). We are going to license the treatment method using the three-drug administration described in the patent to medical institutions from now on.
02/14/2025
Our headquater has moved with business expansion.
12/19/2024
Interview with CEO Yasuyuki Ishii about Japanese cedar pollen allergy was puplished in Jomo newspaper.
bottom of page
